An immunohistochemical assessment of cathepsin D in gastric carcinoma: its impact on clinical prognosis

Cancer. 1997 Jul 15;80(2):179-87. doi: 10.1002/(sici)1097-0142(19970715)80:2<179::aid-cncr2>3.0.co;2-p.

Abstract

Background: In the context of tumor-associated proteolysis, the prognostic value of cathepsin D in breast carcinoma has been studied but its role is controversial in relation to gastrointestinal carcinoma. The aim of the current study was to determine whether cathepsin D is a prognostic parameter for gastric carcinoma, and also to consider interaction with the urokinase-plasminogen activator (uPA) system as an established risk factor for tumor-associated proteolysis.

Methods: In a consecutive prospective series of 203 gastric carcinoma patients, expression of cathepsin D in tumor cells was semiquantitatively analyzed with immunohistochemistry (scored 0-3). Median follow-up time was 31 months (range, 9-56 months). Kaplan-Meier (log rank) and multivariate Cox analyses were used to analyze survival.

Results: Kaplan-Meier analysis (log rank statistics) revealed significant association of increasing cathepsin D detection with poorer disease free survival (P = 0.0042) and poorer overall survival (P = 0.0018) of curatively resected patients. Overall survival of all patients was not significantly correlated. Multivariate analysis of established risk factors for gastric carcinoma, including the uPA system, identified cathepsin D as a new and independent prognostic parameter for disease free survival (P = 0.020; relative risk, 2.98; 95% confidence interval, 1.28-6.91). Plasminogen activator inhibitor type-1 as a representative of the uPA system was confirmed as a strong independent factor for disease free and overall survival. Chi-square analysis showed significant correlation of higher cathepsin D levels with Laurén's diffuse-type carcinomas and strong evidence of uPA receptor in tumor cells. However, a subgroup analysis performed according to Laurén's classification revealed a univariate prognostic impact of cathepsin D on both diffuse and intestinal types without independent value. For patients with high levels of uPA receptor (scores of 2 and 3, n = 132), a highly significant association of increasing evidence of cathepsin D with disease free survival (P < 0.0001) and overall survival (P < 0.0001) was observed for curatively resected patients. Significant association with survival was also observed for all patients (P = 0.0407).

Conclusions: Cathepsin D is a new functional prognostic parameter for gastric carcinoma patients with independent value for disease free survival. Moreover, this study indicates that consideration of more than one tumor-associated protease could lead to a more individualized estimation of risk for carcinoma patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers
  • Cathepsin D / metabolism*
  • Female
  • Humans
  • Immunohistochemistry
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Plasminogen Activators / metabolism
  • Prognosis
  • Proportional Hazards Models
  • Prospective Studies
  • Risk Factors
  • Serine Proteinase Inhibitors / metabolism
  • Stomach Neoplasms / metabolism*
  • Stomach Neoplasms / mortality*
  • Stomach Neoplasms / pathology
  • Survival Analysis
  • Urokinase-Type Plasminogen Activator / metabolism

Substances

  • Biomarkers
  • Serine Proteinase Inhibitors
  • Plasminogen Activators
  • Urokinase-Type Plasminogen Activator
  • Cathepsin D